Loading stock data…
AARD
$3.58-0.01 (-0.28%)
After Hours$3.58+0.00 (+0.00%)· Last close Jun 9
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aardvark Therapeutics, Inc. in the Healthcare sector is trading at $3.58. Wall Street consensus targets $15.44 (9 analysts), implying a +331.4% move over the next 12 months. The stock is currently near its 52-week low of $3.35, remaining 62.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 30 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +331.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 30) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$3.58
Potential Downside
0%
Whystock Fair Value$3.58
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-80.32%
Volume
Today's trading volume
106,258
Recent News
Several Insiders Invested In Aardvark Therapeutics Flagging Positive News
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.1% and
Top Midday Decliners
LanzaTech Global (LNZA) signed a securities purchase agreement with certain institutional investors
FDA hold puts Aardvark Prader-Willi drug in limbo
The company plans to unblind the late-stage study that was halted due to safety concerns, which could lead to an overhaul of its entire development program.
Discover 3 Promising Penny Stocks With Market Caps Over $100M
Over the last 7 days, the United States market has dropped 29%, and in the past year, it is down 82%, though earnings are forecast to grow by 16% annually. Despite these challenging conditions, identifying stocks with solid financials can still offer potential for growth. Penny stocks, often associated with smaller or newer companies, continue to present opportunities for investors seeking hidden value in quality companies. We've selected three examples that combine balance sheet strength...